C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.

Taizo UchimotoTakuya MatsudaKazumasa KomuraWataru FukuokayaTakahiro AdachiYosuke HirasawaTakeshi HashimotoAtsuhiko YoshizawaMasanobu SarutaMamoru HashimotoTakuya HigashioShuya TsuchidaKazuki NishimuraTakuya TsujinoKo NakamuraTatsuo FukushimaKyosuke NishioShutaro YamamotoKosuke IwataniFumihiko UrabeKeiichiro MoriTakafumi YanagisawaShunsuke TsudukiKiyoshi TakaharaTeruo InamotoJun MikiKazutoshi FujitaTakahiro KimuraYoshio OhnoRyoichi ShirokiHirotsugu UemuraHaruhito Azuma

Published in: Targeted oncology (2024)

The evaluation of the CAR from a concise blood examination at the initiation of EV could effectively predict the treatment response to EV in patients with metastatic urothelial carcinoma after the progression of platinum-based chemotherapy and checkpoint inhibitors.

Keyphrases

squamous cell carcinoma
small cell lung cancer
dna damage
cell cycle
locally advanced
combination therapy
rectal cancer